Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
Total Valuation
Gain Therapeutics has a market cap or net worth of $69.62M. The enterprise value is $60.99M.
Market Cap$69.62M
Enterprise Value$60.99M
Share Statistics
Gain Therapeutics has 38,462,086 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,462,086
Owned by Insiders3.33%
Owned by Institutions0.10%
Financial Efficiency
Gain Therapeutics’s return on equity (ROE) is -2.78 and return on invested capital (ROIC) is -239.88%.
Return on Equity (ROE)-2.78
Return on Assets (ROA)-1.68
Return on Invested Capital (ROIC)-239.88%
Return on Capital Employed (ROCE)-2.48
Revenue Per Employee0.00
Profits Per Employee-887.44K
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Gain Therapeutics is ―. Gain Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio6.73
Price to Fair Value6.73
Price to FCF-2.62
Price to Operating Cash Flow-3.66
PEG Ratio0.05
Income Statement
In the last 12 months, Gain Therapeutics had revenue of 0.00 and earned -20.41M in profits. Earnings per share was -0.89.
Revenue0.00
Gross Profit0.00
Operating Income-20.35M
Pretax Income-19.87M
Net Income-20.41M
EBITDA-20.27M
Earnings Per Share (EPS)-0.89
Cash Flow
In the last 12 months, operating cash flow was -17.30M and capital expenditures -945.00, giving a free cash flow of -17.30M billion.
Operating Cash Flow-17.30M
Free Cash Flow-17.30M
Free Cash Flow per Share-0.45
Dividends & Yields
Gain Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.75
52-Week Price Change-27.89%
50-Day Moving Average2.63
200-Day Moving Average2.10
Relative Strength Index (RSI)40.70
Average Volume (3m)878.14K
Important Dates
Gain Therapeutics upcoming earnings date is Mar 19, 2026, After Close (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 19, 2026
Ex-Dividend Date―
Financial Position
Gain Therapeutics as a current ratio of 2.97, with Debt / Equity ratio of 3.06%
Current Ratio2.97
Quick Ratio2.97
Debt to Market Cap<0.01
Net Debt to EBITDA0.48
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Gain Therapeutics has paid 536.82K in taxes.
Income Tax536.82K
Effective Tax Rate-0.03
Enterprise Valuation
Gain Therapeutics EV to EBITDA ratio is -1.96, with an EV/FCF ratio of -2.10.
EV to Sales0.00
EV to EBITDA-1.96
EV to Free Cash Flow-2.10
EV to Operating Cash Flow-2.10
Balance Sheet
Gain Therapeutics has $8.81M in cash and marketable securities with $180.94K in debt, giving a net cash position of $8.63M billion.
Cash & Marketable Securities$8.81M
Total Debt$180.94K
Net Cash$8.63M
Net Cash Per Share$0.22
Tangible Book Value Per Share$0.31
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Gain Therapeutics is $7.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.50
Price Target Upside314.36% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast42.29%